Despite the non-significant statistical difference between LGG and GBM among the remaining 17 regulators, the somatic mutation frequency in GBM on m6A regulators was considered to be more than in LGG, due to the larger sample size of LGG (508) than GBM (495), except HNRNPC, FMR1, and WTAP, which demonstrated that the somatic mutation frequency of GBM patients among m6A regulators tended to be higher than that of LGG patients. This evidence concerns the gene HNRNPC and glioblastoma.